STOCK TITAN

Aptevo Therapeutics Inc - APVO STOCK NEWS

Welcome to our dedicated news page for Aptevo Therapeutics (Ticker: APVO), a resource for investors and traders seeking the latest updates and insights on Aptevo Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aptevo Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aptevo Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.42%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.53%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
none
Aptevo Therapeutics Inc

Nasdaq:APVO

APVO Rankings

APVO Stock Data

2.73M
489.73k
0.77%
8.3%
0.69%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Seattle

About APVO

aptevo therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. we leverage the innovative adaptir™ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients. based in seattle, washington, the company is proud of its empowering work environment, entrepreneurial culture, and proprietary platform technology. as a result, aptevo has been able to attract some of the most innovative minds in the field. many of our team members have notable experience with other pioneering biotech companies including trubion, zymogenetics, immunex, dendreon, and vlst. at aptevo therapeutics, our core values of ownership and collaboration—combined with a history of innovation, dedication, and development—are positioning aptevo therapeutics to develop the science of what’s next in biotechnology.